Open AccessCardiovascular drug therapy and surrogate COVID-19 outcomes: which is the impact of the “miraculous” sodium-glucose co-transporter-2 inhibitors? Author’s reply
Author(s) -
Michał Terlecki,
Wiktoria Wojciechowska,
Marek Klocek,
Michał Kania,
Maciej T. Małecki,
Tomasz Grodzicki,
Marek Rajzer
Publication year - 2021
Publication title -
kardiologia polska
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.527
H-Index - 34
eISSN - 1897-4279
pISSN - 0022-9032
DOI - 10.33963/kp.a2021.0071
Subject(s) - medicine , covid-19 , transporter , drug , surrogate endpoint , pharmacology , intensive care medicine , virology , infectious disease (medical specialty) , disease , biochemistry , chemistry , outbreak , gene
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom